FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Setsu Endoh-Yamagami

Senior Scientist and Head of the iPSC-based Neural Pharmacology & Assay Group FUJIFILM Corporation

Wednesday 4th February 2026

Parkinson’s Disease Model Using Human iPSC-derived Neuron-astrocyte-microglia Tri-cultures

12:10 pm

FUJIFILM Corporation has previously developed human iPSC-derived aged astrocytes exhibiting senescent features, which can be induced into neurotoxic astrocytes by cytokine stimulation
By combining these aged astrocytes with dopaminergic neurons and microglia, we established a tri-culture system that demonstrates α-synuclein-induced cytokine release and neuronal damage, highlighting its potential utility for Parkinson’s disease drug development
FUJIFILM Corporation offers advanced compound evaluation using this novel model, along with opportunities for collaboration in disease modeling and CNS drug development